Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.54 |
| ▸ | ESR1 | P03372 | 4/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.49 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440195 | 0.83 | RPS6KB1 (0.49) | LMNAHTTALDH1A1MEN1NPC1 | |
| SCHEMBL3969719 | 0.75 | HTT (0.41) | LMNAHTTL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL6492889 | 0.73 | SMN1; SMN2 (0.52) | LMNAHTTL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL2494868 | 0.72 | ESR2 (0.62) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL6439732 | 0.72 | ESR2 (0.61) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL6461042 | 0.72 | ESR2 (0.57) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL6440249 | 0.71 | ESR2 (0.91) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL9007262 | 0.71 | ESR2 (0.91) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL6439085 | 0.71 | ESR2 (0.56) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL2502426 | 0.70 | POLB (0.57) | ESR2ESR1GRIA1CACNG8CACNG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002524-A1 | Benzimidazole compounds and their use as estrogen agonists/antagonists | CHESWORTH RICHARD (US) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002524-A1 | Benzimidazole compounds and their use as estrogen agonists/antagonists | ESR1, GPER1, ESR2 | ESR2 3/4885ESR1 1/4885GRIA1 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.